Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania. Show more
Three Bala Plaza East, Bala Cynwyd, PA, 19004, United States
Market Cap
505.9M
52 Wk Range
$1.73 - $6.42
Previous Close
$4.87
Open
$4.87
Volume
1,766,998
Day Range
$4.78 - $5.00
Enterprise Value
373.1M
Cash
136.9M
Avg Qtr Burn
-38.53M
Insider Ownership
0.88%
Institutional Own.
75.21%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Nomlabofusp (CTI-1601) Details Friedreich’s Ataxia | BLA Submission |